questionText: To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled 2024 voluntary scheme for branded medicines pricing, access and growth: summary of the heads of agreement, published on 20 November 2023, what assessment her Department has made of the potential impact of these policies on life science SMEs.
answerText: The Government’s Life Sciences Vision sets out our ambition to develop a globally competitive life sciences investment ecosystem in the United Kingdom. While no assessment has been made, the 2024 voluntary scheme for branded medicines pricing, access and ...
heading: Voluntary Scheme for Branded Medicines Pricing and Access